NASDAQ$ALLO
Allogene Therapeutics Inc. · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2022 and provided a corporate update.
Allogene Therapeutics reported its second quarter financial results, highlighting the anticipated U.S. FDA clearance for a potential pivotal Phase 2 trial of ALLO-501A and the operational status of its commercial-scale manufacturing facility, Cell Forge 1 (CF1). The company ended the quarter with $686 million in cash, cash equivalents, and investments.
- U.S. FDA clearance on potential pivotal Phase 2 trial of ALLO-501A anticipated in coming weeks.
- Cell Forge 1 (CF1) is projected to support the manufacture of ~20,000 doses of AlloCAR T™ products annually at scale.
- Company plans to evaluate potential Phase 2 pivotal study approach and timing for BCMA Program for Multiple Myeloma by Year End.
- Ended Second Quarter with $686 Million in Cash, Cash Equivalents and Investments.
Headline financials
Revenue & EPS history
Allogene · Revenue · Quarterly
$86K
Forward guidance
Allogene anticipates spending to increase in the second half relative to the first half of 2022 and now expects full year GAAP Operating Expenses to be at the low end of the previous range of $360 million and $390 million. Cash burn for 2022 is now expected to be approximately $250 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-5.0%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+23.7%
Q3 2023
Best reaction
-11.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -16.0% | -17.7% | |
| Q4 2025 | -2.8% | -13.0% | +10.1% | |
| Q3 2025 | +10.7% | +17.1% | +36.2% | |
| Q1 2025 | -1.8% | -1.8% | +23.4% | |
| Q4 2024 | +2.6% | -10.6% | -23.3% | |
| Q3 2024 | -4.3% | -11.8% | -32.0% | |
| Q2 2024 | -7.5% | -7.5% | -5.5% | |
| Q1 2024 | +7.2% | +0.4% | -6.9% | |
| Q4 2023 | -4.5% | -10.0% | -22.1% | |
| Q3 2023 | +23.7% | +15.9% | -11.0% | |
| Q2 2023 | +7.3% | -11.3% | -15.4% | |
| Q1 2023 | +20.6% | +18.1% | +4.9% | |
| Q4 2022 | +0.2% | -5.4% | -21.5% | |
| Q3 2022 | -9.9% | -14.2% | -10.5% | |
| Q2 2022 | +1.5% | +8.1% | -3.5% | |
| Q1 2022 | +2.3% | -18.9% | -8.0% | |
| Q4 2021 | -4.8% | -5.9% | -0.7% | |
| Q3 2021 | -0.1% | -5.8% | -12.6% | |
| Q2 2021 | +8.2% | +3.2% | +16.1% | |
| Q1 2021 | -0.7% | -1.4% | -19.0% | |
| Q4 2020 | +0.8% | +0.5% | -1.9% | |
| Q3 2020 | -11.8% | -17.5% | -0.4% | |
| Q2 2020 | +0.3% | -0.6% | -10.9% | |
| Q1 2020 | -0.9% | +8.2% | +38.1% | |
| Q4 2019 | +6.1% | +8.1% | -21.7% | |
| Q3 2019 | -10.5% | -5.5% | +2.1% | |
| Q2 2019 | +4.4% | -0.9% | -7.4% | |
| Q1 2019 | -2.1% | -2.5% | -16.5% | |
| Q4 2018 | -4.7% | -9.3% | -5.7% | |
| Q3 2018 | +3.8% | +8.3% | -5.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro